IL-6/IL-6R as a potential key signaling pathway in prostate cancer development

doi:10.5306/wjco.v2.i12.384

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 2, Issue 12

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (11438)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-1) series.

Item

Count

PDF

581

HTML

10538

Figures (1-2)

196

Tables (1-1)

123

Sum=11438

Dec 10, 2011 (publication date) through Apr 18, 2024

Times Cited of This Article

Times Cited (86)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Guidelines For Clinical Practice

World J Clin Oncol. Dec 10, 2011; 2(12): 384-396
Published online Dec 10, 2011. doi: 10.5306/wjco.v2.i12.384

Full Size Figure Download Figure

Figure 1 Schematic of IL-6 classical and trans-signaling pathway. IL-6: Interleukin 6; JAK: Janus kinase; MAPK: Mitogen-activated protein kinase; PI3K; Phosphatidylinositol 3-kinase; RANKL: Receptor activator of nuclear factor κB ligand; sIL-6R: Soluble IL-6 receptor; STAT3: Signal transducer and activator of transcription 3.

Citation: Azevedo A, Cunha V, Teixeira AL, Medeiros R. IL-6/IL-6R as a potential key signaling pathway in prostate cancer development. World J Clin Oncol 2011; 2(12): 384-396
URL: https://www.wjgnet.com/2218-4333/full/v2/i12/384.htm
DOI: https://dx.doi.org/10.5306/wjco.v2.i12.384